Hennion & Walsh Asset Management, Inc. Bluebird Bio, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$3.02 - $4.05 $29,016 - $38,912	-9,608 Reduced 16.49%	48,666 $147,000
Q2 2023 Aug 09, 2023	SELL	$2.79 - $5.03 $117,319 - $211,511	-42,050 Reduced 41.91%	58,274 $192,000
Q1 2023 Apr 20, 2023	SELL	$3.14 - $8.22 $8,839 - $23,139	-2,815 Reduced 2.73%	100,324 $319,000
Q4 2022 Jan 12, 2023	BUY	$5.77 - $8.49 $59,327 - $87,294	10,282 Added 11.07%	103,139 $714,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $7.39 $8,827 - $17,396	-2,354 Reduced 2.47%	92,857 $588,000
Q2 2022 Jul 19, 2022	BUY	$2.94 - $5.23 $14,214 - $25,287	4,835 Added 5.35%	95,211 $394,000
Q1 2022 Apr 26, 2022	BUY	$4.07 - $10.6 $84,798 - $220,851	20,835 Added 29.96%	90,376 $438,000
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $296,755 - $540,187	33,120 Added 90.94%	69,541 $695,000
Q3 2021 Nov 12, 2021	BUY	$11.24 - $21.0 $140,162 - $261,870	12,470 Added 52.06%	36,421 $696,000
Q2 2021 Aug 13, 2021	BUY	$18.04 - $22.09 $310,775 - $380,544	17,227 Added 256.2%	23,951 $766,000
Q1 2021 May 17, 2021	BUY	$16.59 - $33.89 $111,551 - $227,876	6,724 New	6,724 $203,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.